Inhibrx, Inc. (Nasdaq: INBX), relating to its proposed sale to Sanofi. Under the terms of the agreement, INBX shareholders are expected to receive $30.00 in cash and 0.25 shares of the newly combined company per share they own. Shareholders may also receive a plus one CVR worth up to $5.00 in cash contingent upon certain milestones.